Alx Oncology Holdings (ALXO) financial statements
Net income was -$102M.
Free cash flow was -$84M.
The diluted share count rose 1851% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Alx Oncology Holdings's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $5M | $1M | $0 | $0 | — | — | — |
| Research and development | $11M | $16M | $29M | $60M | $98M | $142M | $116M | $77M |
| Selling, general and admin | $3M | $3M | $15M | $23M | $29M | $28M | $26M | $24M |
| Operating income | -$14M | -$19M | -$44M | -$84M | -$127M | -$170M | -$142M | -$104M |
| Interest expense | — | — | — | $13,000 | $238,000 | $2M | $2M | $2M |
| Pre-tax income | -$14M | -$19M | -$45M | -$83M | -$123M | -$161M | -$135M | -$102M |
| Income tax | $45,000 | $34,000 | $241,000 | -$21,000 | $64,000 | $0 | $0 | $0 |
| Net income | -$14M | -$19M | -$46M | -$83M | -$123M | -$161M | -$135M | -$102M |
| EPS (diluted) | -$6.33 | -$7.56 | -$2.76 | -$2.07 | -$3.03 | -$3.74 | -$2.58 | -$1.90 |
| Diluted shares | 3M | 3M | 18M | 40M | 41M | 43M | 52M | 54M |
| Operating margin | -662.0% | -400.0% | -3694.0% | — | — | — | — | — |
| Net margin | -664.3% | -401.2% | -3869.7% | — | — | — | — | — |
Balance sheet
Fiscal years, from Alx Oncology Holdings's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $8M | $9M | $434M | $364M | $266M | $183M | $128M | $45M |
| Total current assets | — | $10M | $436M | $367M | $271M | $189M | $134M | $51M |
| Property, plant and equipment | — | $860,000 | $52,000 | $897,000 | $4M | $4M | $3M | $1M |
| Total assets | — | $11M | $436M | $380M | $306M | $243M | $148M | $59M |
| Total current liabilities | — | $5M | $6M | $15M | $28M | $36M | $18M | $25M |
| Long-term debt | — | $5M | — | — | $9M | $10M | $9M | $5M |
| Total liabilities | — | $11M | $6M | $17M | $43M | $53M | $34M | $33M |
| Shareholders' equity | -$52M | -$71M | $430M | $363M | $263M | $190M | $114M | $26M |
| Net debt | -$8M | -$4M | -$434M | -$364M | -$39M | -$13M | -$8M | -$7M |
Cash flow
Fiscal years, from Alx Oncology Holdings's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13M | -$14M | -$38M | -$68M | -$89M | -$130M | -$122M | -$84M |
| Capital spending | $653,000 | $353,000 | $31,000 | $666,000 | $1M | $1M | $447,000 | $212,000 |
| Free cash flow | -$14M | -$15M | -$38M | -$69M | -$91M | -$132M | -$122M | -$84M |
| Stock-based compensation | $269,000 | $297,000 | $5M | $14M | $24M | $26M | $27M | $13M |
| Share buybacks (net) | -$6,000 | — | — | — | — | — | — | — |
| Net borrowing | — | $6M | — | — | $10M | — | — | -$435,000 |
| Free cash flow margin | -669.7% | -304.5% | -3242.0% | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ALXO.
Open ALXO in InvestinglyQuestions
How much free cash flow does Alx Oncology Holdings generate?
-$84M in fiscal 2025 (operating cash flow minus capital spending).
From Alx Oncology Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.